Aligos Therapeutics (NASDAQ:ALGS) Now Covered by Analysts at Westpark Capital

Westpark Capital began coverage on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report issued on Thursday morning,Benzinga reports. The brokerage issued a buy rating and a $48.00 target price on the stock.

Several other research analysts have also weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Aligos Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $48.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut Aligos Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, UBS Group assumed coverage on Aligos Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $20.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Aligos Therapeutics Price Performance

NASDAQ:ALGS opened at $7.04 on Thursday. The firm has a market cap of $43.58 million, a price-to-earnings ratio of -0.82 and a beta of 2.67. The firm’s fifty day moving average price is $7.33 and its 200 day moving average price is $8.76. Aligos Therapeutics has a 1-year low of $3.76 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. As a group, analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ALGS. NorthCrest Asset Manangement LLC acquired a new stake in shares of Aligos Therapeutics during the third quarter worth approximately $98,000. Rockefeller Capital Management L.P. grew its position in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Aligos Therapeutics during the third quarter valued at approximately $99,000. HRT Financial LP acquired a new stake in Aligos Therapeutics in the fourth quarter worth $106,000. Finally, DRW Securities LLC acquired a new stake in shares of Aligos Therapeutics in the 4th quarter worth about $111,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.